Experimental cancer vaccine reduces melanoma death or recurrence risk by 42%
The picture shows doctor gives a vaccine dose to a patient. — Reuters/FileModerna and Merck have said that their mRNA cancer vaccine, when combined with Merck's widely used immunotherapy, cut the risk of melanoma death or recurrence by 42% in a large trial, potentially...
0

0 Comments
Recommended Comments
There are no comments to display.
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.